Pembrolizumab (anti-PD-1)  (Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1))

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

PDCD1/PD-1/CD279

Deferoxamine (Df) chelates pembrolizumab and does not block or alter the binding affinity or specificity of pembrolizumab to CD4+ and CD8+ T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Experiments confirmed that ⁸⁹Zr-Df-Pembrolizumab has a specific activity of 740 mBq/mg antibody. mBq is the unit of radioactivity, used to measure radioactive decay^[2].
Positron emitter ⁸⁹Zr-labeled deferoxamine (Df)-Pembrolizumab, through PET imaging, its biodistribution has be dynamically tracked. The results shows that pembrolizumab remained stable in the blood circulation and accumulated most in liver and spleen tissues. And it shows similar biodistribution and pharmacokinetics in mice and rat^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5133  [NCBI]

Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.341 kDa

Liquid

Colorless to light yellow

[Pembrolizumab (anti-PD-1)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow cytometry analysis of PD-1 overexpression HEK293 cells labelling PD-1 with Pembrolizumab at 67nM (Red). Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.  [Content Brief]

  [2]. England CG, et al. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168.  [Content Brief]